Neuroblastoma is the most common extracranial malignancy of childhood. Patients with high-risk disease receive multimodal treatment including chemotherapy combinations containing alkylating agents and topoisomerase inhibitors with potential for inducing therapy-related malignancy later in life. Most commonly, cytogenetic changes of pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia involve chromosome 5 or 7. Here we report a novel case of therapy-related myelodysplastic syndrome/acute myeloid leukemia 30 months after treatment for high-risk neuroblastoma with biphenotypic cell surface markers and a not yet described translocation t(1;6)(q25;p23).
*Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine/Texas Children’s Hospital
†Department of Pathology and Immunology
‡Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX
The authors declare no conflict of interest.
Reprints: Sarah B. Whittle, MD, 6701 Fannin Street, Suite 1580.13, Houston, TX 77030 (e-mail: email@example.com).
Received January 14, 2017
Accepted July 12, 2017